Study of Effectiveness of Mexyn-A

This study has been completed.
Sponsor:
Information provided by:
Evangelical Synod Medical Centre
ClinicalTrials.gov Identifier:
NCT00568204
First received: November 30, 2007
Last updated: October 16, 2013
Last verified: October 2013

November 30, 2007
October 16, 2013
March 2002
Not Provided
Treating Pruritus [ Time Frame: three days ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00568204 on ClinicalTrials.gov Archive Site
measuring itch-free period after applying the new treatment, effect on sleep disturbance [ Time Frame: three days ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Study of Effectiveness of Mexyn-A
Proof of Concept of MEXYN-A

Atomised Methoxymethane-in-Aqua (MEXYN-A) a new topical self-chilled, non-steroidal, non-flammable, pressurised spray which embodies in one simultaneous application, most of the currently recognised and effective chemical, mechanical and thermal anti-pruritic therapies and hydrotherapy.

The primary clinical endpoint was to establish MEXYN-A efficacy and safety in abolishing or reducing pruritus related to cutaneous diseases, insect bites and poison ivy, within few seconds of the application. The secondary endpoint was to measure the itch free period as a result of the new intervention.

Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Pruritus
Device: Mexyn-A
Atomised topical self-chilled pressurised spray
Other Name: Clearitch, Itcharret, itchclear, Magicool-Plus
Experimental: 1
Mexyn-A
Intervention: Device: Mexyn-A
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
279
September 2005
Not Provided

Inclusion Criteria:

  • Patients suffering from severe itching due to : Atopic Dermatitis, contact dermatitis, psoriasis, urticaria, xerosis, prickly heat, genital pruritus, chicken pox, aquagenic pruritus, lichen planus, poison ivey, insect bites.
  • Past experience with the use of at least one conventional medication for pruritus or conventional medication for the same disorder patients suffered.

Exclusion Criteria:

  • Patients who have taken any anti-pruritic drug during the month prior to participation.
  • Patients who have taken drugs for any reason for 2 days prior to participating in the study.
Both
5 Years to 80 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Egypt
 
NCT00568204
EvangelicalSynodMC
Yes
Dr Ihab Akhnoukh M.D., Evangelical Synod Medical Centre
Evangelical Synod Medical Centre
Not Provided
Principal Investigator: Ihab Akhnoukh Evangelical Synod Medical Centre
Study Director: Ashraf Khella Harpur Memorial Hospital
Evangelical Synod Medical Centre
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP